<DOC>
	<DOCNO>NCT00872235</DOCNO>
	<brief_summary>This open-label , balance , randomize , two-treatment , four-period , two-sequence , single dose , crossover fully replicate study conduct fixed-dose combination quinapril 20 mg hydrochlorothiazide 25 mg tablet OHM Laboratories Inc. ( division Ranbaxy Laboratories Limited ) Accuretic 20-25 mg tablet Parke-Davis ( division Pfizer Inc. ) healthy , adult , human , male , subject fed condition .</brief_summary>
	<brief_title>Bioequivalence Study Quinapril Hydrochloride 20 mg Hydrochlorothiazide 25 mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>The subject receive single oral dose either Test Reference product , contain fixed-dose combination Quinapril 20 mg Hydrochlorothiazide 25 mg overnight fast least 10 hour . The study drug administer per SAS generate Randomization Code , 30 minute serve high-fat high-calorie breakfast supervision train Medical Officer period.Blood sample collect predose interval 72 hour dose . A 7-day interval maintain dose Study Periods I-IV . During course study safety parameter assess vital sign , physical examination , medical history , clinical laboratory safety test ( hematology , biochemical parameter urine analysis ) base line . Laboratory parameter hematology biochemistry repeat sodium &amp; potassium level estimate 24 hour post dose last period study . A total 40 subject randomize receive fixed-dose combination quinapril 20 mg hydrochlorothiazide 25 mg tablet 37 subject complete four period study .</detailed_description>
	<mesh_term>Quinapril</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>1 . Be age range 1845 year . 2 . Be neither overweight underweight his/her height per Life Insurance Corporation India height/weight chart nonmedical case . 3 . Have voluntarily give write informed consent participate study . 4 . Be normal health determine medical history physical examination subject perform within 14 day prior commencement study . 1 . History allergy quinapril , hydrochlorothiazide , sulfonamide derive drug related ACE inhibitor . 2 . History anuria , gout dry cough . 3 . History diarrhea vomit last one week . 4 . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . 5 . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . 6 . Presence value , significantly different normal , reference range ( define Appendix 5 ) and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . 7 . Positive urinary screen test drug abuse ( opiates cannabinoids ) . 8 . Presence value , significantly different normal , reference range ( define Appendix 5 ) and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . 9 . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . 10 . Clinically abnormal ECG Chest Xray . 11 . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes , glaucoma angioedema due cause . 12 . History psychiatric illness may impair ability provide write informed consent . 13 . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . 14 . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . 15 . Use enzyme modifying drug within 30 day prior Day 1 study . 16 . Participation clinical trial within 12 week precede Day 1 study . 17 . A haemoglobin concentration le 7 % low limit reference range e.g . 13 gm % reference range 1418 gm screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Bioequivalence fixed-dose combination quinapril 20 mg hydrochlorothiazide 25 mg tablet</keyword>
</DOC>